Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain)

Abstract

The aim of this study was to determine the prevalence of varicella IgG antibodies in the population of Catalonia, and the variables associated. The study was carried out in 2002 in a representative sample of juvenile (5–14 years) and adult population (≥15 years) of Catalonia (Spain). The global prevalence determined by ELISA test was 95.5% (95% CI 94.7–96.3). The prevalence increased with age, from 82% (95% CI 77.0–87.0) in the 5–9 years age up to 99.4% (95% CI 98.2–100) in >64 years of age. No statistically significant differences in the seroprevalence according to the sociodemographic variables were observed. The current strategy of vaccinating preadolescents at 12 years of age who have not suffered the disease will require more than 30 years to cover the current gap immunity in adolescents and young adults. Vaccination with two doses of vaccine for all adolescents and adults ≤ 50 years who report not having suffered the disease during childhood should be considered.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Heininger U, Seward JF (2006) Varicella. Lancet 368:1365–1375

  2. 2.

    Salleras L, Pujals JM, Salleras M (2003) Vacuna antivarizela-zoster. In: Salleras L (eds) Vacunaciones preventivas, 2nd edn. Masson, Barcelona, pp 311–330

  3. 3.

    Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections. Med Microbiol Immunol 196:95–102

  4. 4.

    Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clinical Microbiol Rev 18:70–80

  5. 5.

    Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell Science Limited, London

  6. 6.

    Office of Population Census and Surveys (1980) Classification of occupations. Office of Population Census, London

  7. 7.

    Demmeler GJ, Steinberg SP, Blum G, Gershon AA (1988) A rapid enzyme-linked immunosorbent assay for detecting antibodies to varicella-zoster virus. J Infect Dis 157:211–212

  8. 8.

    Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL (2001) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19:183–188

  9. 9.

    Wharton M (1996) The epidemiology of varicella-zoster virus infection. Infect Dis Clin North Am 10:571–581

  10. 10.

    Ooi PL, Goh KT, Doraisingham S, Ling AE (1992) Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23:22–25

  11. 11.

    Pachón I, Amela C, de Ory F, León P, Alonso M (1998) Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Año 1996. Bol Epidemiol Semanal 6:93–104

  12. 12.

    Gil A, González A, Dal-Ré R, Ortega P, Domínguez V (1998) Prevalence of antibodies against varicella zoster, Herpes simples (Types 1 and 2), hepatitis B and hepatitis A virases among Spanish adolescents. J Infect 36:53–6

  13. 13.

    Díez-Domingo J, Gil A, San-Martín M et al (2005) Seroprevalence of varicella among children and adolescents in Valencia, Spain: reliability of the parent’s reported history and the medical file for identification of potential candidates for vaccination. Hum Vaccin 1:204–206

  14. 14.

    Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19:3097–3103

  15. 15.

    Svahn A, Bergren J, Parke A, Storsaeter J, Thorstensson R, Linde A (2006) Changes in seroprevalence to four herpesvirus over 30 years in Swedish children aged 9–12 years. J Clin Virol 37:118–123

  16. 16.

    Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN (2007) Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol 14:1057–1061

  17. 17.

    Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:1214124

  18. 18.

    Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588–593

  19. 19.

    Mossong J, Putz L, Schneider F (2004) Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol Infect 132:1121

  20. 20.

    de Melker H, Berbers G, Hahne S et al (2006) The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946–3952

  21. 21.

    Khoshnood B, Debruyne M, Lançon F et al (2006) Seroprevalence of varicella in the French population. Pediatr Infect Dis J 25:41–44

  22. 22.

    Gabuti G, Penna C, Rossi MA et al (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126:433–440

  23. 23.

    Gürgöze MK, Yılmaz E, Gödekmerdan A, Akça Z, Doğan Y, Akarsu S, Denizmen Aygün A (2006) Seroprevalence of mumps, varicella and rubella antibodies in children 1–16 years of age in eastern Turkey. Turk J Pediatr 48:185–188

  24. 24.

    Kurugol Z, Koturoglu G, Aksit S, Ozacar T (2007) Varicella seroprevalence in Turkish population in Cyprus. Acta Paediatr 96:861–863

  25. 25.

    Breuer J (2004) Varicella zoster virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD (eds) Principles and practice of clinical virology, 5th edn. Wiley, Chichester, pp 53–83

  26. 26.

    Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS (2006) Seroepidemiology of varicella zoster in Israel prior to large-scale use of varicella vaccines. Infection 34:208–213

  27. 27.

    Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I et al (2007) The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25:7866–7872

  28. 28.

    Borras E, Domínguez A, Batalla J, Torner N, Cardeñosa N, Nebot M, Plasencia A, Salleras L (2007) Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 25:3240–3243

  29. 29.

    Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535–545

  30. 30.

    Plans- Rubió P (2004) Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia (Spain). Vaccine 22:4002–4013

  31. 31.

    Plans P, Espuñes J, Plasencia A, Salleras L (2007) Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women childbearing age. Br J Obstet Gynaecol 114:122–127

Download references

Acknowledgments

We would like to thank the participating schools, the doctors, nurses and administrative staff of the primary health care centers who collaborated in obtaining clinical samples and the hospital laboratories who stored the samples.

The study was partly funded by a grant from the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (RCESP C03/09, Epidemiology and Public Health Research Network).

Author information

Correspondence to Neus Cardeñosa.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Salleras, L., Domínguez, À., Plans, P. et al. Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain). Med Microbiol Immunol 197, 329–333 (2008). https://doi.org/10.1007/s00430-007-0064-z

Download citation

Keywords

  • Varicella zoster virus
  • Seroprevalence